IGF2BP2 Drives Cell Cycle Progression in Triple‐Negative Breast Cancer by Recruiting EIF4A1 to Promote the m6A‐Modified CDK6 Translation Initiation Process. This evidence concerns the gene IGF2BP2 and breast carcinoma.